Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20060866 | 0.88 | GPR119 (0.44) | FFAR1GPR119HCRTR1HCRTR2HRH3 | |
| SCHEMBL20060927 | 0.82 | GPR119 (0.47) | GPR119HRH3NR1H2NR1H3 | |
| SCHEMBL20061055 | 0.82 | GPR119 (0.47) | GPR119HRH3NR1H2NR1H3 | |
| SCHEMBL30451702 | 0.81 | NR1H2 (0.53) | FFAR1GPR119HCRTR1HCRTR2HRH3 | |
| SCHEMBL20061107 | 0.81 | NR1H2 (0.53) | FFAR1GPR119HCRTR1HCRTR2HRH3 | |
| SCHEMBL22310606 | 0.81 | NR1H2 (0.53) | FFAR1GPR119HCRTR1HCRTR2HRH3 | |
| SCHEMBL22284457 | 0.81 | NR1H2 (0.53) | FFAR1GPR119HCRTR1HCRTR2HRH3 | |
| SCHEMBL22310513 | 0.79 | GPR119 (0.52) | GPR119HRH3NR1H2NR1H3 | |
| SCHEMBL20060931 | 0.79 | HCRTR1 (0.39) | FFAR1GPR119HCRTR1HCRTR2 | |
| SCHEMBL20060864 | 0.79 | GPR119 (0.43) | GPR119HRH3NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018071317-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |